Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 11/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.35 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 2/20 | 0.33 |
| ▸ | SRC | P12931 | 2/20 | 0.33 |
| ▸ | TEK | Q02763 | 2/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.33 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.33 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.33 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.33 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.33 |
| ▸ | DUSP22 | Q9NRW4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13745732 | 0.91 | KDR (0.49) | KDRPTPN11PTPN2PTPN1PTPRC | |
| SCHEMBL13745686 | 0.88 | KDR (0.35) | KDRPTPN11GSK3BAXLCDK8 | |
| SCHEMBL13745780 | 0.88 | CAMKK2 (0.41) | KDRLCKTEK | |
| SCHEMBL13745726 | 0.88 | BRD4 (0.37) | KDRGSK3BLCKTEK | |
| SCHEMBL13746535 | 0.84 | CAMKK2 (0.41) | KDR | |
| SCHEMBL13746292 | 0.84 | GSK3B (0.34) | PTPN11GSK3BAXLCDK8TNIK | |
| SCHEMBL13745719 | 0.83 | CAMKK2 (0.40) | KDR | |
| SCHEMBL13746062 | 0.82 | CAMKK2 (0.38) | PTPN11 | |
| SCHEMBL13746565 | 0.82 | CAMKK2 (0.39) | KDRPTPN11 | |
| SCHEMBL13745690 | 0.82 | GSK3B (0.34) | GSK3BAXLCDK8TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | KDR 3757/4885PTPN11 1694/4885MAP4K1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.